|
Anticuerpos monoclonales asociados a quimioterapia en el tratamiento de primera línea del cáncer colorrectal metastásico: eficacia, seguridad y eficiencia comparadas [Monoclonal antibodies associated with chemotherapy as first line therapy in metastatic colorectal cancer: relative efficacy, safety and efficiency] |
Castillo Muñoz MA, Ubago Pérez R, Navarro Caballero JA, Márquez Peláez S, Beltrán Calvo C, Flores Moreno S, Rodríguez López R, Romero Tabares A |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Castillo Muñoz MA, Ubago Pérez R, Navarro Caballero JA, Márquez Peláez S, Beltrán Calvo C, Flores Moreno S, Rodríguez López R, Romero Tabares A. Anticuerpos monoclonales asociados a quimioterapia en el tratamiento de primera línea del cáncer colorrectal metastásico: eficacia, seguridad y eficiencia comparadas. [Monoclonal antibodies associated with chemotherapy as first line therapy in metastatic colorectal cancer: relative efficacy, safety and efficiency] Seville: Andalusian Agency for Health Technology Assessment (AETSA). 2011/6. 2013 Authors' objectives To evaluate the efficacy of bevacizumab, cetuximab and panitumumab, for the first line therapy in metastatic colorectal cancer, in adult patients who tolerate fluoropyrimidin-based chemotherapy with irinotecan and/or oxaliplatin versus this chemotherapy.
To evaluate the safety of bevacizumab, cetuximab and panitumumab, in metastatic colorectal cancer.
To evaluate the efficiency of each monoclonal antibody (bevacizumab, cetuximab and panitumumab), for the first line therapy in metastatic colorectal cancer, in adult patients who tolerate fluoropyrimidin-based chemotherapy with irinotecan and/or oxaliplatin versus this chemotherapy.
Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Humans Language Published Spanish Country of organisation Spain English summary An English language summary is available. Address for correspondence Agencia de Evaluacion de Tecnologias Sanitarias Sanitarias de Andalucia (AETSA) Av/ Luis Montoto No 89 CP 41007 Sevilla (Spain) Tel. +34 955 921 581 Fax + 34 955 923 572 Email: aetsa.csalud@juntadeandalucia.es AccessionNumber 32013000745 Date abstract record published 23/10/2013 |
|
|
|